Caplacizumab in acquired thrombotic thrombocytopenic purpura: Dose adjustment based on von Willebrand factor level
Med Clin (Barc). 2023 Sep 29;161(6):267-268.
doi: 10.1016/j.medcli.2023.04.017.
Epub 2023 Jun 27.
[Article in
English,
Spanish]
Affiliations
- 1 Servicio de Farmacia, Àrea del Medicament, Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, España. Electronic address: malbanell@clinic.cat.
- 2 Servicio de Farmacia, Àrea del Medicament, Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, España.
- 3 Aféresis y Unidad de Terapia Celular, Departamento de Hemoterapia y Hemostasia, ICMHO, Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, España.
No abstract available
MeSH terms
-
Humans
-
Plasma Exchange
-
Purpura, Thrombotic Thrombocytopenic* / drug therapy
-
Single-Domain Antibodies*
-
von Willebrand Factor
Substances
-
von Willebrand Factor
-
caplacizumab
-
Single-Domain Antibodies
Supplementary concepts
-
Thrombotic thrombocytopenic purpura, acquired